Another pharmaceutical company charged with promoting its drugs off-label decides to settle a false claims act lawsuit. Boehringer Ingelheim (BI) was charged with promoting several of its drugs for unapproved uses including Micardis, Aggrenox, Atrovent and Combivent.
@Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. http://www.boehringer-ingelheim.com/